Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.